With Nearly $400 Billion in Cash and a New CEO, Is Berkshire Hathaway Stock a Buy?

Berkshire Hathaway ended the quarter with a record cash pile above $397 billion, up from $373 billion at year-end, while remaining a net seller of stocks. The company repurchased only about $234 million of stock and reported operating income up 18% to $11.3 billion, helped by a 29% jump in insurance underwriting profits. Management reiterated no plans to break up the conglomerate or rush into AI, leaving the stock largely a valuation-and-cash deployment story.

Analysis

Berkshire’s swollen cash balance is less a sign of prudence than an implicit statement that the best marginal use of capital is currently outside public markets. That matters because a mega-cap balance sheet sitting idle removes a natural buyer from the market, which can subtly weaken support for high-quality cyclicals and capital-light compounders that would otherwise be natural Berkshire targets in a drawdown. The buyback pace is too small to matter for per-share optics, so the stock is still trading more like a bond proxy on trust in underwriting and capital allocation than a classic equity rerating story.

The more important second-order signal is that management is telegraphing a slower adoption curve on AI and a higher bar for deploying capital into tech. That is constructive for incumbents with real industrial distribution or data moats, but it also means Berkshire likely will not participate in the next leg of AI capex monetization unless it can buy infrastructure-adjacent assets at scale. In practice, that leaves the firm exposed to under-earning its cash in a market where front-end yields are already high and liquidity can be rotated into higher-beta names more quickly.

For AAPL, the key issue is not near-term demand but the absence of a large, price-insensitive buyer if Berkshire ever rebalances further; that removes a marginal bid from a name that often trades on buyback support and ecosystem durability. For NDAQ, the gambling-atmosphere comment is a reminder that options/prediction markets can crowd out traditional listed equity turnover; that can help derivatives revenues but hurts cash equity engagement, so the stock’s reaction should be more muted than headline AI enthusiasm implies. The contrarian takeaway is that the market may be overestimating how quickly Abel changes capital deployment; the near-term setup is still one of patience, not transformation, which caps multiple expansion.

Key Decisions for Investors

• Stay underweight BRK.B for the next 3-6 months; the equity has limited catalyst support while cash earns less than the implied opportunity cost of owning a cheap but inert compounder.
• Relative-value long AAPL / short BRK.B over 1-2 quarters: AAPL retains direct buyback support and stronger AI monetization optionality, while BRK.B is more likely to remain a capital accumulator than a redeployer; target modest outperformance, not directional conviction.
• Trim tactical exposure to NDAQ on rallies; the stock may benefit from activity, but the market is likely already pricing the structural growth in trading/derivatives, leaving limited upside unless retail speculative volumes accelerate further.
• If BRK.B sells off 5-8% on any renewed disappointment around capital returns, use it to buy a 6-12 month call spread rather than stock: upside is driven by deployment optionality, but the timing is too uncertain for outright leverage.
• Avoid chasing NVDA/INTC on Berkshire’s AI caution alone; the slower adoption stance is company-specific, not a broad signal that AI capex is rolling over, so any short in semis should be reserved for evidence of demand deceleration rather than narrative skepticism.